Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 plus chemotherapy in advanced NSCLC
NCT04054531Phase 2Unknown
- Sponsor
- Alphamab Oncology
- Start
- Sep 2019
- Primary completion
- Mar 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in non-small cell lung cancer (NSCLC), sponsored by Alphamab Oncology. Status: unknown.
02
Drugs
erfonrilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04054531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054531.